

Question for written answer E-014423/2015
to the Commission
Rule 130
Notis Marias (ECR)

Subject: Greek pharmaceuticals on the verge of extinction

Pursuant to Article 168 TFEU on public health, the European Parliament and the Council have adopted measures to specify high quality and safety standards for medicinal products and equipment intended for medical purposes.

By imposing a third MoU on Greece, the troika intends to deal a critical blow to one of the last pillars that could bring about economic recovery, i.e. the pharmaceutical industry.

By its intervention, the troika requires a new pricing system to be used for medicinal products, aiming to make domestic production unprofitable, thus eliminating the Greek pharmaceutical industry.

If the Greek pharmaceutical industry is affected, the persons employed by that industry will be added to the multitudes of Greek unemployed people and the millions of Greek poor people. Moreover, Greek medicinal products will be replaced by more expensive imported ones, whose quality is, in several instances, questionable. And expensive imported medicinal products will become some sort of luxury for impoverished people.

In view of the above, I would like to ask the Commission as a member of the troika: will the Commission continue to insist on its failed MoU policy, thus damaging the Greek pharmaceutical industry?